Sowell Financial Services’s BioCryst Pharmaceuticals BCRX Stock Holding History

Sowell Financial Services’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-30,167	Closed	-$418K	–	196
2021 Q4	$418K	Buy	30,167 +9	+0%	+$119	0.02%	454
2021 Q3	$433K	Sell	30,158 -2,227	-7%	-$35.1K	0.03%	415
2021 Q2	$512K	Buy	32,385 +7,749	+31%	+$105K	0.03%	414
2021 Q1	$318K	Buy	24,636 +12,941	+111%	+$133K	0.01%	820
2020 Q4	$87K	Buy	11,695 +3,328	+40%	+$17.2K	﹤0.01%	1205
2020 Q3	$29K	Buy	8,367 +7,183	+607%	+$30.8K	﹤0.01%	1390
2020 Q2	$6K	Buy	+1,184	New	+$4.73K	﹤0.01%	1831

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sowell Financial Services's BCRX Position: Q1 2022 in Review

Sowell Financial Services sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2022, closing a stake of 30,167 shares — an estimated $418K sold.

Sowell Financial Services first reported a position in BCRX in Q2 2020 and held it in 7 quarters. The position peaked at $512K in Q2 2021. 233 funds tracked by Wall St. Rank hold BCRX as of Q1 2022.

Sowell Financial Services reported no remaining BioCryst Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Sowell Financial Services sold 30,167 BioCryst Pharmaceuticals shares in Q1 2022, an estimated $418K.
Sowell Financial Services first reported a position in BioCryst Pharmaceuticals in Q2 2020 and held it in 7 quarters.
Sowell Financial Services's BioCryst Pharmaceuticals position peaked at $512K in Q2 2021.
233 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2022.

Based on Sowell Financial Services's 13F filing for Q1 2022, filed 13 May 2022.